Bringing the Oncology Community Together

Dr. Mayer on Tivozanib in Kidney and Breast Cancer

Erica L. Mayer, MD, MPH
Published Online: Friday, November 30, 2012
Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

A phase I study investigated tivozanib as a monotherapy for patients with renal cell carcinoma. Tivozanib was active and well tolerated, demonstrating common toxicities of angiogenesis inhibitors such as hypertension and hoarse voice.

In a phase III trial, patients with renal cell carcinoma were randomized to tivozanib or sorafenib. Patients in the tivozanib arm had superior progression-free survival (PFS) (11.9 months vs 9.1 months) and needed fewer dose reductions.

Tivozanib has also been studied in breast cancer. In a phase I dose escalation trial, tivozanib was combined with weekly paclitaxel and demonstrated an overall response rate of 28 percent. The most common toxicities experienced in the trial were fatigue, gastrointestinal toxicity, mild neutropenia, and neuropathy. The maximum tolerated doses identified were tivozanib at 1.5 mg/day and paclitaxel at 90 mg/m2 weekly.

Related Articles
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
New ASCO Guideline Expands Recommendation for SLN Biopsy Use in Early Stage Breast Cancer
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.